Alliance of regenerative medicine 2024 overview of stereotactic NSGY gene and cell therapy assets + a little more
a small amount of data for clearpoint nerds and bag holders
Hello,
on the slides below I highlight some early-stage gene and cell therapy products, initial pieces of data and some interpretations of early data. The common thread that binds all of these products together is of course ClearPoint. If unfamiliar, the idea is simply that some of the devices being used here will be co-labeled onto the drugs label for delivery, so it’s a great example of regulatory capture of pharma & biotech product with a medical devices company. The side effect being that others growth capex has the opportunity to permanently and dramatically increases the value of ClearPoint’s own products.
As it stands today these programs are lumpy, hard to track, some are not public, and so the way I think about the tempo of average number patients by quarter for any unique product follows a rather conservative series over obscenely long periods of time. It may be around 6-12 years prior to a drug receiving more than several dozen product sales to an individual product, so their day to day and quarter to quarter impact is small. Even if you presume a wide breadth of active trials, the quarter-to-quarter impact would still be relatively small unless several phase 3 trials were ongoing.
It’s been 2 years since I checked in on some of these, so I’m quite happy to hear an almost uniform response across separate disease types and the companies supporting their development costs. I’ve attached the source video of most recent conferences these slides were sourced from. I’ll be following developments in this space going forward as I have been for nearly 4 years.
Now’s probably the best point in recent history for ClearPoint as they’re entering the OR with exclusive marketing rights for a best-in-class laser ablation device. This is something that required several things that have collectively taken years to come together. What is happening now unshackles ClearPoint from the prison of exclusively being in specialized MRI operating room environments.
This device itself is a very strong pitch to get into any OR and will possibly attract 6 dozen plus active customers who want to use this laser every day of the week. This is the Bruce Lee of stereotactic neurosurgery taking off his weighted clothing and squaring up.
I’d suspect that once in the OR with a substantial number of installations (let’s say > 30 installations) with this device, historical surgery counts ClearPoint has been involved with should be eclipsed by an order of magnitude within 36 months. But that’s not what I’ll be talking about today…
A couple weeks ago there was a meeting with the alliance of regenerative medicine, a number of whom are Clearpoint customers. I make a couple flags of these presentations.
Thank you for your support as always.
PS if you’re already scouring for data on this name, you won’t find assets discussed here you’re unfamiliar with. There was no partner I could find that was clearly using stereotaxis to localize a drug infusion. Maybe I missed one, but I don’t think I did.